DEP cabazitaxel presentation at ASCO 2024 Annual Meeting
Released
Released
Announcement PDF
ASX Announcement
DEP® cabazitaxel presentation at ASCO 2024
Annual Meeting
Melbourne, Australia; 3 June 2024: Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a
copy of the DEP® cabazitaxel presentation that was delivered at the American Society of Clinical
Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of an oral
abstract session showcasing the final results of the DEP® cabazitaxel Phase 1/2 clinical trial.
The ASCO Meeting is the most comprehensive gathering of oncology clinicians, researchers, and
pharmaceutical companies in the world. It provides a platform to hear the latest breakthroughs
and advancements in cancer treatment. Only a small proportion of submitted abstracts are
accepted for presentation at the ASCO Annual Meeting. This year, fewer than 4% of these
accepted abstracts were designated for full or rapid oral presentation.
It is a significant achievement that both DEP® cabazitaxel and DEP® irinotecan abstracts were
selected for oral presentation at the ASCO Meeting, a demonstration of the quality and potential
clinical impact of the findings.
The DEP® cabazitaxel ASCO Meeting abstract (#3004) has been published in the Journal of
Clinical Oncology (JCO) (Volume 42, Number 16)1. Professor James Spicer, MBBS FRCP PhD,
professor of experimental cancer medicine at King’s College London, consultant in medical
oncology, and Principal Investigator of the DEP® cabazitaxel trial at Guy’s and St Thomas’ NHS
Foundation Trust in London, delivered the presentation over the weekend.
The presentation is appended.
1
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3004
About Starpharma
Starpharma (ASX: SPL, OTCQX: SPHRY) is dedicated to helping patients with significant illnesses, such as cancer, achieve improved
health outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure,
high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma uses its dendrimer technology to develop novel therapeutics and to enhance the performance of existing
pharmaceuticals. The Company’s portfolio includes multiple clinical-stage oncology products, which utilise its Dendrimer Enhanced
Product (‘DEP®’) drug delivery technology, as well as marketed products, including VIRALEZE™ and VivaGel® BV, which utilise
SPL7013, a proprietary dendrimer with antimicrobial properties. Starpharma’s DEP ® drug delivery platform is being used to enhance
the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by Chair,
Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set
to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or
implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results,
performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future re gulatory filings will
satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product
candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s
expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial
results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our
ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public
pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and
business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the
date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new
information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for
illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the
likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or
shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
2
Efficacy and safety of dendrimer-enhanced
cabazitaxel (DEP CTX) in patients with
advanced solid cancers; a Phase 1/2 trial
James Spicer1, David J. Pinato2, Martin D. Forster3, Anthony M. Joshua4, James Korolewicz5, Karam
Aboud6, Cienne Morton1, Jia Liu4, Rasha Cosman4, Nicola J. Main7, Julia Le Meur7, Jeremy R.A. Paull7,
Stephanie R. Edmondson7, Robert H. Jones6
1King’s College London, Guy’s Hospital, London, UK, 2Imperial College London, London, UK, 3University College London (UCL) Cancer Institute, UCL Hospital NHS Trust,
London, UK, 4The Kinghorn Cancer Centre, St Vincent’s Hospital, Sydney, Australia, 5University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, 6Velindre
Cancer Centre and Cardiff University, Cardiff, UK, 7Starpharma Pty Ltd, Abbotsford, Australia
James Spicer FRCP PhD
Study funded and sponsored by Starpharma Pty Ltd
PRESENTED BY:
James Spicer FRCP PhD
Dendrimer nanoparticle delivery of cabazitaxel (DEP CTX)
• 3D lysine polymer provides a scaffold for targeting payloads including
cytotoxics to tumor microenvironment
• Cabazitaxel is a taxane approved for treatment of prostate cancer
• We conducted a Phase 1/2 trial of DEP CTX in advanced solid tumors
• Safety compares favourably with standard cabazitaxel
• Efficacy in patients with tumors including prostate, ovary and upper GI
PRESENTED BY:
James Spicer FRCP PhD
Dendrimer platform1
DEP CTX designed to improve safety and efficacy of cytotoxic payload
• Branched poly-lysine polymer
DEP dendrimer (1:1 ratio CTX:PEG)
• Scalable, precise manufacturing in concentric layers
▪ 5 generations, 64 attachment points per dendrimer
• Covalent linkage (1:1) to:
▪ cabazitaxel (CTX) - linker renders payload inert until released
▪ PEG - solubility without polysorbate; molecular weight/PK
Hydrolysable
linker
PEG2000
Cabazitaxel
• Hydrolysis of linker in tumor interstitium releases free drug
10-15 nm
102kDa
1. Kaminskas et al, Nanomedicine 2011, 6(6):1063-1084
PRESENTED BY:
James Spicer FRCP PhD
Preclinical selective delivery and anti-tumor activity
Size-dependent tumor
accumulation1,2
Tumor accumulation
PET-CT image
DEP CTX enhanced
efficacy: xenograft model
DEP dendrimer-drug conjugate
89Zr-labelled DEP CTX
saline
S-CTX (9 mg/kg)
S-CTX (11 mg/kg)
DEP CTX (9 mg/kg)
DU145 (human
prostate cancer)
xenograft
NORMAL TISSUE
•
•
48 hours post IV
injection
TUMOR
DEP CTX preferentially escapes from
permeable tumor vasculature
• DEP CTX or s-CTX IV on days 1, 8 & 15; n=10/group
• SCID mice; DU-145 human prostate xenograft
Prolonged retention in tumor
interstitium
1. Iyer et al., Drug Disc Today 2006, 11:17-18):812-818
2. Kaminskas et al., Nanomedicine 2011, 6(6):1063-1084
PRESENTED BY:
James Spicer FRCP PhD
Dendrimer cabazitaxel Phase 1/2 trial
•
Phase 1 - primary objective: safety profile; MTD & DLTs; secondary objectives: preliminary efficacy, PK
•
Single patient cohorts, followed by 3+3 escalation1. Expansion cohorts in selected tumor types
Phase 1 Dose Escalation Cohorts
Dose Level (mg/m2 CTX)
G4 neutropenia
•
DEP CTX 3-weekly IV infusion
•
no corticosteroid pre-medication
•
no routine use of G-CSF
G3 febrile
neutropenia
Phase 1 outcomes (n=14)
25
G3 neutropenia - non-DLT
20
RP2D
15
• One patient
• No DLT
• Non-DLT AE
• DLT
10
5
2
•
DLTs: G4 neutropenia, G3 febrile neutropenia
•
RP2D: 20 mg/m2 cabazitaxel, Q3W
Phase 2 dose expansion (n=75)
Prostate
(n=25)
Ovary
(n=22)
Esophagogastric
(n=15)
Other
(n=13*)
* hepatobiliary, head & neck, lung, thymic carcinoma
Patients
PRESENTED BY:
James Spicer FRCP PhD
1. Jones RH, Pinato DJ, Joshua A, et al. Ann Oncol, 2022:33(suppl_7):S616-S652
Phase 2 patient characteristics
PATIENT BASELINE CHARACTERISTICS
PROSTATE
OVARIAN
EGC
HNSCC
HEPATOBILIARY
OTHER*
TOTAL
Patients enrolled (n, %)
25 (33%)
22 (29%)
15 (20%)
7 (9%)
4 (5%)
2 (3%)
75 (100%)
Median
(range)
73
(57-83)
62
(43-76)
61
(25 – 73)
60
(49-69)
65
(57-75)
73
(66-80)
65
(25-83)
Male
25 (100%)
0 (100%)
10 (67%)
6 (86%)
2 (50%)
1 (50%)
44 (59%)
Female
0 (0%)
22 (100%)
5 (33%)
1 (14%)
2 (50%)
1 (50%)
31 (41%)
0
15 (60%)
12 (55%)
8 (53.3%)
4 (57%)
2 (50%)
0
41 (55%)
1
10 (40%)
10 (45%)
7 (46.7%)
3 (43%)
2 (50%)
2 (100%)
34 (45%)
Median
(range)
4
(2-9)
4
(1-11)
1
(1-3)
3
(2-4)
2
(1-4)
3
(2-4)
3
(1-11)
Platinum
2 (8%)
22 (100%)
13 (87%)
7 (100%)
4 (100%)
2 (100%)
49 (65%)
Taxane
24 (96%)
22 (100%)
3 (20%)
4 (57%)
0 (0%)
1 (50%)
54 (72%)
Prior surgery (n, %)
Any
7 (28%)
21 (95%)
6 (40%)
3 (43%)
4 (100%)
2 (100%)
43 (57%)
Radiotherapy (n, %)
Any
21 (84%)
7 (32%)
6 (60%)
6 (86%)
2 (50%)
1 (50%)
46 (61%)
Age (years)
Sex (n, %)
ECOG PS
Prior lines of therapy
Prior systemic exposure
(n, %)
*lung and thymic carcinoma
PRESENTED BY:
James Spicer FRCP PhD
DEP CTX Phase 2 safety
•
•
•
G3/4 neutropenia 23% (16% in prostate)
Febrile neutropenia 1% (none in prostate)
G-CSF:
- primary prophylaxis: 0%
- any: 9%
•
Treatment-related AEs in ≥10% patients, or ≥ Grade 3 (n=75)
Most common symptomatic AEs:
fatigue, PSN, nausea; mostly
mild/moderate
•
>90% of PSN was G1/2
•
G3/4 non-heme TRAEs 21%
•
No prominent hypersensitivity signal
or anaphylaxis: no routine steroid
premedication
•
G1 alopecia 4% (3/75)
PRESENTED BY:
Anemia
Neutropenia
Thrombocytopenia
Lymphopenia
Leukopenia
Febrile Neutropenia
10.7%
44.0%
22.7%
2.7%
37.3%
17.3%
All Grades
2.7%8.0%
1.3%
≥ Grade 3
1.3%
5.3%
Fatigue
5.3%
Peripheral Neuropathy
Nausea 1.3%
4.0%
29.3%
Vomiting
2.7%
29.3%
Diarrhea
21.3%
Decreased Appetite 1.3%
18.7%
AST Increased 1.3%
14.7%
Constipation 0%
12.0%
ALT Increased 1.3%
2.7%
Sepsis
Upper GI heamorrhage 1.3%
Esophago-pulmonary fistula 1.3%
Pneumonia (aspiration) 1.3%
0
20
59.9%
59.9%
48.0%
40
Patients (%)
James Spicer FRCP PhD
60
80
Pharmacokinetics
Phase 1 PK:
Linear PK parameters across dose range (2-25 mg/m2 CTX)
No evidence of cycle-to-cycle accumulation
Concentration (ng/mL)
(ng/mL)
Concentration
DEP CTX
CTX(mean
(mean
± SD)
DEP Pharmacokinetics
CTX Pharmacokinetics–-Free
Free CTX
± SD)
Cycle 1
100
10
1
Slow-release depot
0
Total CTX
(mean)
19.2
9,870
Cmax (ng/mL)
AUCinf (ng.h/mL)
1,190
173,000
t1/2 (h)
~100
>100
10-fold lower Cmax for
free CTX from DEP
10
Higher t1/2 for free
CTX from DEP
1
0
PRESENTED BY:
300
Free CTX from DEP
s-CTX
100
Concentration (ng/mL)
Free CTX
(mean)
200
Time (hrs)
Free CTX vs standard CTX†
– simulated population PK profiles
DEP CTX 20mg/m2
PK at RP2D
100
100
200
James Spicer FRCP PhD
† Ferron et al., Cancer Chemother Pharmacol, 2013; 71:681-692
300
hrs
Phase 2 anti-tumor activity
mCRPC
Ovary
EGC
HNSCC
(n = 25)
(n = 22)
(n = 15)
(n = 7)
Hepatobiliary
Evaluable, n
17
18
10
3
RECIST measurable, n
12
17
10
ORR %
16.7%
17.6%
[95% CI]
[2.1 - 48.4]
DCR %
[95% CI]
Other†
Total
(n = 2)
(n = 75)
1
2
51
3
1
2
45
30.0%
0.0%
0.0%
50.0%
20.0%
[3.8 - 43.4]
[6.7 - 65.2]
[0.0 - 70.8]
[0.0 - 97.5]
[1.3 - 98.7]
[9.6 - 34.6]
70.6%
66.7%
80.0%
33.3%
100%
100%
70.6%
[44.0 - 89.7]
[41.0 - 86.7]
[44.4 - 97.5]
[0.8 - 90.6]
[2.5 - 100.0]
[15.8 - 100.0]
[56.2 - 82.5]
Median PFS (mths)
4.4*
3.1
4.0
1.7
0.8
6.3
3.8
[95% CI]
[3.8 - 5.9]
[1.9 - 4.0]
[1.9 - 5.6]
[1.2 - 1.9]
[0.5 - 9.3]
[- ; -]
[2.1 - 4.1]
Median OS (mths)
14.7
Not
reached
8.6
2.1
1.9
9.0
9.0
[4.5 - 12.0]
[1.5 - 15.1]
[0.6 -]
[- ; -]
[7.0 - 15.1]
[95% CI]
[6.2 - 19.6]
[4.9 - -]
*Composite disease progression outcome: RECIST soft tumor / bone / PSA (RECIST v1.1, PCWG3)
Evaluable: received ≥ 1 dose of DEP CTX and had a post-baseline scan at ≥8 weeks,
or efficacy measurement for prostate patients.
RECIST-measurable at baseline (ORR data)
PRESENTED BY:
James Spicer FRCP PhD
(n = 4)
HNSCC: Head & Neck Squamous Cell Cancers
† Other cancers: thymic carcinoma, NSCLC
Phase 2 anti-tumor activity – RECIST
Prostate
Ovary
EGC
Other
Response rate = 20% (9/45)
PRESENTED BY:
James Spicer FRCP PhD
Phase 2 prostate cancer
Prostate
• PSA reduction in 91%
>50% reduction (‘PSA50’) in 52%
•
•
62% reduction abdominal LNs
87% PSA reduction
Baseline
On treatment
• 87% stable or improved bone disease
• Durable PRs and SDs up to 55 weeks
1. Scher H et al. J Clin Oncol 2016
PRESENTED BY:
James Spicer FRCP PhD
Conclusions
• Dendrimer cabazitaxel is safe and well tolerated:
▪ no pre-medication (due to lack of toxic excipients)
▪ potential for less severe myelosuppression compared with standard CTX
- despite little use of G-CSF
▪ no AEs related to dendrimer scaffold
• Clinical benefit even in patients previously exposed to taxanes
• DEP platform has potential to deliver other cytotoxics, targeted
therapies & radioisotopes
• Further clinical development of DEP CTX is justified
PRESENTED BY:
James Spicer FRCP PhD
Acknowledgements
• All patients participating in the study, and their families
• All investigators and research personnel who conducted this trial
• Sponsor: Starpharma Pty Ltd
PRESENTED BY:
James Spicer FRCP PhD
Share your feedback
Discover